Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jun 2025 Status changed from recruiting to active, no longer recruiting.
08 May 2025 According to Acadia Pharmaceuticals media release, if results of this trial are positive, the Company anticipates submitting an NDA to the USFDA in Q1 2026.
08 May 2025 According to Acadia Pharmaceuticals media release, as a result of favorable enrollment trends in this trial, the company has accelerated the timing for this study and topline results are now expected in early Q4 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com